Archive · 30 Jul 2026
Mankind Pharma Q1 Profit Climbs 30% on Domestic Surge
Mankind Pharma is a company that makes medicines.
In the first part of the year, it earned 30% more money than it did a year before.
This happened because its sales grew steadily and it made more money on each sale.
The company did especially well with medicines for long‑term illnesses in India.
It also sold more medicines for sudden illnesses, which helped balance out slower sales of everyday health products.
All of this made the company’s profit higher than before.
Mankind Pharma’s first‑quarter net profit increased 30% year‑on‑year.
Revenue grew steadily and operating margins improved.
Strong domestic chronic‑disease business drove much of the profit rise.
A rebound in acute‑therapy sales offset slower consumer‑healthcare growth.
Overall profit growth reflects solid domestic performance.
- Who
- Mankind Pharma
- What
- First‑quarter net profit rose 30% year‑on‑year
- When
- First quarter
- Where
- Domestic (India)
- Why
- Steady revenue growth, improved margins, strong chronic business, and a rebound in acute therapies
- Net profit increase
- 30% year‑on‑year
- Operating margins
- improved
- Domestic chronic business
- strong performance
- Acute therapies
- rebound
- Consumer healthcare
- slower growth